Astellas Paying $5.9bn For Iveric To Boost Ophthalmology Presence

Eyes Post-Xtandi Revenues

 
• By Ian Haydock and Lisa Takagi
  
Astellas notes a high expectation for Iveric Bio's clinical candidate ACP
Astellas eyes high-need ophthalmology indication and another revenue pillar in Iveric deal • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip